The prevention of cellular toxicity associated with local metabolism or transport, which cannot be addressed by routine monitoring, is worth investigating further.
Introduction
By definition, pharmacogenetics describes the influence of variations in the DNA sequence on drug response. This includes: (i) the study of the pharmacogenetic-pharmacokinetic relationships (i.e., the influence of the genome on the fate of the drug in the body); (ii) the study of the pharmacogenetic-pharmacodynamic relationships (i.e., the influence of the genome on the molecular or cellular effects of the drug); and (iii) pharmacogenomics that studies the global influence of genes involved in the pharmacokinetic (PK) and pharmacodynamic (PD) phases on drug effects, i.e. a complex and multigenic phenotype.
The vast majority of pharmacogenetic studies in general have been focused on cytochrome P450 enzymes, and then on phase II (conjugation) enzymes. More recently, research has been oriented towards the role of membrane transporters in drug intestinal absorption, passage in the metabolising organs or accumulation in target tissues. Pharmacogeneticpharmacodynamic studies have been less explored, but this field is now booming with specific approaches and models, including: the definition of networks of genes involved in drug response (so-called -pharmacogenes‖) through the analysis of electronic databases to generate a "Genome-scale candidate gene lists for pharmacogenomics‖ 1 ; and high-throughput
As highlighted before, UGT2B7 only catalyzes the production of AcMPAG, the minor but reactive metabolite of MPA. The association between UGT2B7 polymorphisms and MMFrelated digestive adverse effects was thus investigated. Several SNPs have been identified in UGT2B7. Among them, the nonsynonymous c.802C>T SNP (rs7439366; UGT2B7*2) in exon 2 results in a histidine-to-tyrosine substitution at codon 268. At least 6 other SNPs have been identified, in the UGT2B7 promoter region (c. 44 . It was reported that two of these SNPs (c.-842G>A and c.802C>T), in complete linkage disequilibrium, result in a significant increase of AcMPAG production by human liver microsomes 45 . A study conducted in 67 renal transplant recipients of different ethnicities (Caucasian, African American, Hispanic, others) employing a selfadministered questionnaire, -the gastrointestinal symptom rating scale‖, suggested that patients with the UGT2B7 c.802C>T variant genotype were protected from the gastrointestinal adverse effects of MPA regardless of the mycophenolic acid formulation or concurrent calcineurin inhibitor administered 43 . In the specific case of diarrhea, the scale score was however not associated with the UGT2B7 genotypes. At least two other studies have reported no association between UGT2B7 c.-842G>A and the occurrence of MMF related-diarrhea in renal transplant recipients 42, 46 . In the study from van Agteren et al.,
AcMPAG concentrations were included in the analysis, and no association was found either.
The role of the UGT2B7-catalysed formation of AcMPAG in the digestive side effects of MPA thus remains unclear.
As an intestinal MPA metabolizing enzyme, UGT1A8 was also identified as a candidate gene that might have an impact on MMF digestive adverse events. Two main variant alleles were described in this gene (UGT1A8*2 and UGT1A8*3), each bearing a missense SNP at nucleotides 518 (C>G; A 173 G) and 830 (G>A; C 277 Y), respectively 47 . UGT1A8*3 is rare (e.g., 21 . In a long-term cohort of renal transplants UGT1A8*2 (but not UGT1A8*3) was associated with a reduced incidence of diarrhea, as was the administration of ciclosporin (as opposed to tacrolimus or sirolimus). These results suggest that a possible inhibition of the biliary excretion of MPA metabolites by ciclosporin and a decreased intestinal production of these metabolites in UGT1A8*2 carriers may be protective factors against MMF-induced diarrhea 42 .
Pharmacogenetics of MPA and efficacy in kidney transplant recipients.
Given the high expression of UGT1A9 in the liver and the kidney, and its major role in MPAG formation, genetic polymorphisms in this enzyme are expected to influence MPA total clearance and thus patient exposure to the drug. A change in MPAG production may also indirectly affect MPA pharmacokinetics, both by increasing its disposition and by modifying the extent of its enterohepatic cycling.
The UGT1A9 SNPs which were studied in relation to MPA pharmacokinetics are the promoter c.-275T>A/-2152C>T, c.-1887T>G and c.-440C>T/-331T>C SNPs, the c.98T>C
coding SNP, and the IVS1+399 intronic SNP. The significant effects of two common SNPs in the UGT1A9 promoter (c.-275T>A; rs6714486 and c.-2152C>T; rs17868320) on MPA exposure are probably the most clinically pertinent, but the exact mechanism associated with the change in MPA pharmacokinetics is unclear 48 . These SNPs were associated with 52 . In this study, the rs2278294 variant allele carriers also had a 1.6-fold increased risk of leucopenia. The fact that BPAR and leucopenia were inversely associated to the same SNP reinforces the pertinence of this finding: the rs2278294 may protect patients from developing an immunological reaction against the allograft by favoring low lymphocyte levels, hence leucopenia.
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A third study conducted in 82 Japanese renal transplant recipients has investigated the association of these two SNPs with the incidence of subclinical acute rejection diagnosed by a biopsy examination 29 days after transplantation 60 . Day-time and night-time MPA pharmacokinetic data obtained within 24 h of the biopsy (day 28) was included in the analysis. The rs2278293 or rs2278294 SNPs were not found to be associated with the incidence of subclinical acute rejection. However, when the authors stratified their analysis based on the AUC range of MPA during day and night-time periods, a significant influence of the rs2278293 genotype on the incidence of subclinical acute rejection was found in patients with high night-time exposure to MPA (>60µg.h.l -1 ), while a similar trend was observed in patients with high day-time exposure to MPA. The authors mentioned in their discussion the limitations of their study, which include the unique period of AUC measurement at day 28 and the lack of statistical power due to the small sample size. One can also regret that exposure data and genotypes were not tested simultaneously using multivariate analysis rather than in stratified analyses.
Calcineurin inhibitors
Ciclosporin and tacrolimus have considerably improved graft outcome in solid organ transplantation. However, their clinical benefits are balanced by their adverse effects, mainly their nephrotoxicity which remains a major problem in all types of solid organ transplantation.
Metabolism and disposition
Ciclosporin is subject to extensive phase 1 metabolism by CYP3A4 and CYP3A5 61 with approximately 90% of the oral dose eliminated through the bile as metabolites and only 1% as unchanged ciclosporin 62 . Ciclosporin is a substrate for the P-glycoprotein (permeability glycoprotein, abbreviated as P-gp), a member of the ATP-binding cassette (ABC) 
Impact of CYP3A polymorphisms on the efficacy and toxicity of calcineurin inhibitors
CYP3A5 gene expression is the main factor affecting CYP3A overall metabolism. CYP3A5 is expressed in only approximately 10 % of Caucasians as a result of a frequent mutation of adenosine to guanosine at position 6986 within intron 3 of the CYP3A5 gene (rs776746). This SNP results in a splicing defect, leading to a truncated protein with no enzyme activity 70 .
Therefore, only individuals with at least one CYP3A5*1 allele actually express the CYP3A5 protein at a significant level, with large differences in prevalence across ethnicities (5-30%
CYP3A5 expressers in Caucasians, 50-80% in African Americans and Chinese people) 71 . A very large number of studies investigated the association of the CYP3A5*1/*3 polymorphism and ciclosporin or tacrolimus pharmacokinetics in renal transplantation.
Two recent meta-analyses 72, 73 concluded that the CYP3A5*3 allele was associated, to a moderate extent, with increased ciclosporin C 0 /dose or C 2 /dose and reduced mean daily doses.
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The second meta-analysis also studied the association of the variant with the incidence of acute rejection and found no such association. The consequence of CYP3A5*3 on ciclosporin pharmacokinetics may not be of major extent and is likely to be compensated by routine monitoring and dose adjustment.
In contrast to ciclosporin, a strong association between CYP3A5*1/*3 and tacrolimus pharmacokinetics has been demonstrated in multiple studies conducted in renal transplant patients [73] [74] [75] [76] [77] [78] [79] [80] . The dose required to reach the therapeutic concentration range was estimated to be twice as much in carriers of at least one active CYP3A5 allele than in non-carriers [74] [75] [76] [77] 
Impact of ABCB1 polymorphisms on the efficacy and toxicity of calcineurin inhibitors
The influence of ABCB1 SNPs on ciclosporin or tacrolimus pharmacokinetics remains uncertain. Again, any genetic variability in P-gp-mediated drug absorption or elimination is most probably compensated for by routine drug monitoring 82 . However, ABCB1
polymorphisms may directly influence the efficacy or toxicity of calcineurin inhibitors.
Crettol et al. described higher ciclosporin concentrations in the lymphocytes of carriers of the ABCB1 c.3435C>T SNP 83 , suggesting that ciclosporin activity may be affected by this polymorphism independently of its effect on the drug bioavailability or clearance. In a very large scale study involving 832 renal transplant recipients, it was found that the recipient ABCB1 haplotype gathering the exon 12, 21 and 26 alleles, regarded as a more reliable genetic marker than any of these three SNPs alone 84 , predicted acute graft rejection 85 .
In addition, P-gp activity in the kidney graft, which carries the donor's and not the recipient's genome, may contribute to the nephrotoxicity of calcineurin inhibitors. A recent study in renal transplant patients treated with tacrolimus showed that a higher IF/TA grade was found over the first 3 years post-transplantation when both the donor and the recipient were homozygous for the ABCB1 c.3435C>T SNP (OR=3.9; CI95% 2.0-7.6, p<0.001), while there was no association with tacrolimus exposure 88 . Degradation of the renal graft function was also quicker when the donor, the recipient and above all both were carriers of the 3435T variant. The authors proposed that P-gp in tubular epithelial cells influences local tacrolimus accumulation and, in addition, suggested that the recipient ABCB1 polymorphisms might also contribute to graft injury because of the high prevalence of epithelial chimerism after kidney transplantation. However, the only significant determinants of graft survival were acute T cell-mediated and antibody-mediated rejections. We refer the reader to a recent review article on the pharmacogenetics of calcineurin inhibitors-associated nephrotoxicity by Hesselink DA et al. 89 for further reading.
Pharmacogenetics of the calcineurin pathway
Calcineurin is a calmodulin-regulated protein phosphatase composed of two subunits Numerous SNPs have also been described in the different proteins involved in the cellular effect of calcineurin inhibitors through the international HapMap project 93 . However, to the best of our knowledge, none was studied in the context of ciclosporin or tacrolimus effects.
mTOR inhibitors (ImTORs)
Sirolimus (also known as rapamycin) is currently indicated as a preventive treatment of graft with inherent nephrotoxicity not identified in pre-clinical studies 95, 96 . Consequently, the use of ImTORs has actually been restricted to particular conditions so far. The potential of pharmacogenetics for these drugs is important.
Metabolism and disposition
Sirolimus is metabolized by the intestinal 97 and hepatic CYP3A enzymes 98 , with no significant contribution of the metabolites to the pharmacological activity of the drug.
Experiments using recombinant P450 showed that CYP3A4 is a more efficient catalyst of sirolimus metabolism than CYP3A5 (intrinsic clearance of sirolimus depletion: 2.34 vs. 0.66 µl/min/pmol P450) 99 .
Everolimus is similarly metabolized by CYP3A4 and to a lesser extent CYP3A5 100 .
Both drugs are P-gp substrates 101 , which may limit their intestinal absorption 101 . The primary elimination route of ImTORs is through the bile. Hepatic extraction may not involve active transporters 102 , so much so that everolimus and sirolimus have very low affinities for OATP1B1 and 1B3 (personal data). Canalicular excretion of these two drugs or their metabolites probably involves P-gp. In the kidney, P-gp is not expected to play a significant role in the pharmacokinetics of ImTORs since renal elimination is not their primary disposition pathway. However, its inhibition by sirolimus enhances the nephrotoxicity of ciclosporin when the two drugs are coadministered 103 .
Impact of CYP3A polymorphisms on the efficacy and toxicity of ImTORs
The association between CYP3A5*3 alleles and sirolimus dose requirement was investigated in 149 renal transplant recipients, mostly of European descent 104 . The authors only found a significant association with sirolimus C 0 /dose in the subgroup of 69 patients undergoing a sirolimus-based rescue therapy with low-dose corticosteroids and taking no calcineurin inhibitor. No association was found in patients on ciclosporin or tacrolimus suggesting that
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the pharmacogenetic effect may be abrogated by pharmacokinetic drug-drug interactions.
Acute rejection, anemia, dyslipidemia, thrombocytopenia or graft function were not significantly influenced by this polymorphism. However, patients had to be on sirolimus for three months before being enrolled, which means that patients in whom sirolimus had to be interrupted because of side effects (if any) were not studied.
Another study was conducted in 85 renal transplant recipients on sirolimus, of whom 38 received sirolimus as de novo therapy and 47 were switched from a calcineurin inhibitor to sirolimus, mainly for chronic allograft nephropathy or neoplasia 76 . No association between CYP3A5*3 and sirolimus C trough /dose was found, neither in the whole population nor in the sub-groups. We also conducted a prospective study in 47 renal transplant recipients on sirolimus and mycophenolate mofetil, without calcineurin inhibitor 105 . In all patients, a detailed pharmacokinetic profile was collected over the first nine hours post-dose, at 3 months or more after transplantation. Lower AUC 0-9h /dose, C trough /dose and C max /dose values were found in CYP3A5 expressers (p = 0.008, 0.01 and 0.02, respectively). These significant differences between CYP3A5 genotypes were still obtained when normalizing sirolimus concentrations for hemoglobin levels (owing to the high affinity of sirolimus for red blood cells). However, there was no association between the CYP3A5 genotype and clinical findings, except for a trend towards a higher leucopenia incidence in non-expressers.
In summary, these in vivo results suggest that the CYP3A5*3 genotype has a strong influence on sirolimus bioavailability in both de novo and stable renal transplant patients, provided they are not combined with calcineurin inhibitors, which may abolish this effect (although this still needs to be confirmed). Despite the fact that no association with clinical outcome was found, the determination of this genotype for a priori dose adjustment of sirolimus may be useful
given the long half-life of this drugAlthough less data are currently available regarding everolimus, it seems that the CYP3A5*3 genotype has no marked influence on everolimus pharmacokinetics. We recently investigated this association in 28 stable renal transplants and found that the CYP3A5*3 polymorphism did not influence everolimus dose requirement, exposure or dose-normalized exposure 100 . Further experimental studies with genotyped human liver microsomes confirmed that the CYP3A5*3 polymorphism has no significant influence on everolimus metabolism 100 . No association with clinical outcome is thus expected.
Impact of the ABCB1 polymorphisms on the efficacy and toxicity of ImTORs
Two studies in renal transplant recipients of Chinese (n=47) 106 and (mostly) Caucasian (n=149) 104 origins showed no significant association of the ABCB1 c.3435C>T SNP with sirolimus C trough /dose. In another study conducted in 85 patients, no association was found between sirolimus C trough /dose and any of the ABCB1 exon 12, exon 21, and exon 26 SNPs, nor with their haplotype 76 . Also, there was no association between these three SNPs and any clinical outcome (acute rejection, anemia, dyslipidemia, thrombocytopenia or graft function) 104 . In summary, there does not seem to be any ABCB1 pharmacogenetic effect on sirolimus pharmacokinetics or effects in vivo, although P-gp may limit its intracellular passage, as suggested by in vitro experiments. Other experimental data suggest that ciclosporin or another strong P-gp inhibitor such as verapamil might unveil the influence of the 3435C>T SNP on sirolimus pharmacokinetics or intracellular transport, owing to altered P-gp folding in the membrane 107 . Hence, association studies in patients coadministered sirolimus and ciclosporin might yield more interesting results.
To the best of our knowledge, no study of the consequences of genetic polymorphisms in ABCB1 regarding everolimus pharmacokinetics or effects has been reported.
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Pharmacogenetics of the mTOR pathway
The mTOR, also known as the FRAP (FKBP-rapamycin-associated) protein regulates protein synthesis through the phosphorylation and inactivation of the repressor of m-RNA translation -eukaryotic initiation factor 4E binding protein‖, and through the phosphorylation and activation of the phosphatidyl-inositol 3-kinase-p70 ribosomal S6 protein kinase (p70s6K). In particular, p70s6K regulates the cellular response to IL-2. mTOR forms a stoichiometric complex with RAPTOR which has a positive role in signaling to the downstream effector p70sS6K, maintenance of cell size, and mTOR protein expression. The association of RAPTOR with mTOR also negatively regulates the mTOR kinase activity. Finally, ImTORs act by forming an inhibitory complex with the intracellular receptor FK-BP12 which subsequently binds a region in the C-terminus of m-TOR termed FRB (FKBP12-Rapamycin Binding). This causes dephosphorylation and inactivation of the p70s6 kinase activity.
Mutations of the gene encoding mTOR, FK-BP12, P70s6K or RAPTOR might confer a resistant phenotype to these drugs as was demonstrated in mammalian cell lines 108 . However, to our knowledge no association study between such polymorphisms and sirolimus or everolimus effects has been published so far.
Conclusion
Current knowledge about the impact of pharmacogenetics or pharmacogenomics and clinical covariates on the clinical outcome of renal transplant recipients can be summarized as follows:
-Genotyping CYP3A5*1/*3 may help detect patients at risk of tacrolimus underexposure, although the clinical benefit of genotyping is still unclear.
-Genotyping a couple of UGT1A9 promoter SNPs may help reduce the acute rejection rate in kidney transplant recipients on mycophenolate-mofetil, whether combined with inserm-00577136, version 1 -16 Mar 2011 ciclosporin or tacrolimus, provided mycophenolate is not dose-adjusted. Indeed, MPA AUC monitoring is expected to compensate for differences in exposure and abolish this pharmacogenetic-outcome association.
-The UGT1A8*3 polymorphism is linked with the incidence of diarrhea in patients on mycophenolate mofetil, which in turn may lead to drastic dose decreases or to drug discontinuation. Consequently, genotyping this gene might be useful to either avoid giving MMF in UGT1A8*2 carriers, or to combine MMF with ciclosporin rather than tacrolimus or ImTORs in these patients, as this drug has apparently a protective effect against mycophenolate-induced diarrhea.
-The IMPDH I rs2278294 SNP, and possibly also the rs2278293 SNP are significantly associated with a lower acute rejection rate and a higher incidence of leucopenia, which might be used to select a lower MMF dose, or target a lower MPA exposure in carriers of either of these SNPs.
-Genotyping for the ABCB1 1236T/2677T/3435T haplotype, and maybe for the cyclophilin A c.-11C>G SNP, should help detect patients with an increased risk of ciclosporin nephrotoxicity and hence avoid this drug, provided the other immunosuppressants are devoid of such associations.
-There are already hints that tacrolimus nephrotoxicity may also be enhanced by the donor and recipient ABCB1 polymorphisms.
-The influence on ciclosporin or tacrolimus efficacy or side effects of polymorphisms in the proteins of the calcineurin pathway has not been investigated so far, apart from that of cyclophilin A polymorphisms.
-The influence on sirolimus or everolimus efficacy or side effects of polymorphisms in the proteins of the mTOR pathway, or even in CYP3A5 which strongly affects sirolimus pharmacokinetics, has not yet been investigated either.
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However, for the pharmacogenetics of immunosuppressive drugs to come to the clinics, comparative, randomized clinical trials evaluating the impact on patient outcome of treatment personalization based on the abovementioned pharmacogenetic tests versus standard of care
will be necessary to demonstrate their clinical relevance and convince physicians caring for the patients to prescribe them … and regulatory agencies to authorize them. Moreover, such pharmacogenetic trials, as well as routine pharmacogenetic treatment personalization may require analyzing the donor, or both the donor and recipient DNA, which renders matters more complex both technically and ethically.
Pharmacogenetics has been envisaged as a possible tool for treatment personalization, in addition to, or sometimes as a replacement for, therapeutic drug monitoring. However, this literature review shows that the current level of clinical evidence is not high enough yet to recommend pharmacogenetic personalization of immunosuppressive regimens in kidney transplant recipients.
Expert Opinion
The Finally, genome-wide associations studies (GWAS) may help find genetic factors involved in the response of, or tolerance to, immunosuppressive drugs and concerning genes coding for proteins involved in the regulation of the immunological response at large, which should also be regarded as pharmacogenetics.
Article highlight box -Introduction: immunosuppressants are drugs with a narrow therapeutic range and a large inter-individual response variability, which has prompted pharmacogenetic studies, mostly with regards to their dose-concentration relationships. However, some studies have dealt with genetic variability in IS efficacy and response, which are reviewed herein.
Mycophenolic acid: polymorphisms in UGT1A9 and IMPDH I were found to have a significant influence on the incidence of acute rejection, while a polymorphism in UGT1A8 protected patients from drug-induced diarrhea.
Calcineurin inhibitors: polymorphisms in the recipient and above all the donor ABCB1 genes (coding for the P-glycoprotein) were reported to enhance the nephrotoxicity of these drugs and, in patients on ciclosporin, favor graft loss.
ImTORs: the influence of polymorphisms in metabolizing enzymes and proteins of the mTOR pathway on the clinical outcome of patients on sirolimus or everolimus
has not yet been investigated.
Conclusion: Before these pharmacogenetic associations can be used for treatment personalization, they will have to be validated prospectively. 
